GlassScriptPhysician profile
David T Page
NPI 1114920287
$1,919.95
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $135 · 2021: $369 · 2022: $469 · 2023: $415 · 2024: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.82 | 2021-2024 | |
| Glaxosmithkline, LLC. | $284.41 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $184.42 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $179.59 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.31 | 2022-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Irhythm Technologies, INC. | $83.19 | 2022 | |
| Astellas Pharma US INC | $79.73 | 2019-2024 | Veozah |
| Lilly USA, LLC | $59.63 | 2019-2020 | |
| Amgen INC. | $49.40 | 2019-2021 | |
| Mannkind Corporation | $45.04 | 2022-2023 | Afrezza |
| Allergan, INC. | $44.87 | 2020 | |
| Sanofi-Aventis U.S. LLC | $35.34 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $28.21 | 2022-2024 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.34 | 2021 | |
| Amarin Pharma, INC. | $26.96 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $25.31 | 2021 | |
| Abbott Laboratories | $23.24 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $22.83 | 2023 | |
| Genentech USA, INC. | $18.97 | 2019 | |
| Insulet Corporation | $18.87 | 2024 | Omnipod |
| Sanofi Pasteur INC. | $16.73 | 2023 | |
| Lundbeck LLC | $16.73 | 2023 | Vyepti |
| Exact Sciences Corporation | $16.63 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.59 | 2024 | Rexulti |
| Phadia US INC. | $15.68 | 2020 | |
| Ibsa Pharma INC. | $14.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.18 | 2021 | |
| Merck Sharp & Dohme LLC | $13.05 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.93 | 2023 | Austedo |
| Arbor Pharmaceuticals, INC. | $12.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2019 | |
| Mylan Specialty L.P. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.